ICD-10-CM Code C68.9

Malignant neoplasm of urinary organ, unspecified

Version 2020 Billable Code Neoplasm Malignant Primary

Valid for Submission

C68.9 is a billable code used to specify a medical diagnosis of malignant neoplasm of urinary organ, unspecified. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code C68.9 might also be used to specify conditions or terms like malignant neoplasm of urinary organ, malignant tumor of urinary system, metastatic urothelial carcinoma, primary malignant neoplasm of urinary system, t1: urinary tract tumor invades subepithelial connective tissue, ta: noninvasive papillary carcinoma , etc

The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: urinary organ or system .

ICD-10:C68.9
Short Description:Malignant neoplasm of urinary organ, unspecified
Long Description:Malignant neoplasm of urinary organ, unspecified

Tabular List of Diseases and Injuries

The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C68.9:

Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Malignant neoplasm of urinary system NOS

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Malignant neoplasm of urinary organ
  • Malignant tumor of urinary system
  • Metastatic urothelial carcinoma
  • Primary malignant neoplasm of urinary system
  • T1: Urinary tract tumor invades subepithelial connective tissue
  • Ta: Noninvasive papillary carcinoma

Diagnostic Related Groups

The ICD-10 code C68.9 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2020.

  • 656 - KIDNEY AND URETER PROCEDURES FOR NEOPLASM WITH MCC
  • 657 - KIDNEY AND URETER PROCEDURES FOR NEOPLASM WITH CC
  • 658 - KIDNEY AND URETER PROCEDURES FOR NEOPLASM WITHOUT CC/MCC

Convert C68.9 to ICD-9

  • 189.9 - Mal neo urinary NOS

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of urinary tract (C64-C68)
      • Malignant neoplasm of other and unspecified urinary organs (C68)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Table of Neoplasms

The code C68.9 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Neoplasm, neoplastic Malignant
Primary
Malignant
Secondary
CaInSitu Benign Uncertain
Behavior
Unspecified
Behavior
»urinary organ or system
C68.9C79.10D09.10D30.9D41.9D49.59

Information for Patients


Bladder Cancer

The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States.

Symptoms include

  • Blood in your urine
  • A frequent urge to urinate
  • Pain when you urinate
  • Low back pain

Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk.

Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer.

NIH: National Cancer Institute


[Learn More]

Kidney Cancer

You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys.

Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time.

You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice

  • Blood in your urine
  • A lump in your abdomen
  • Weight loss for no reason
  • Pain in your side that does not go away
  • Loss of appetite

Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy.

Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute


[Learn More]